Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
Guggenheim Cuts Price Target on Tetraphase Pharma (TTPH) Following Disappointing cUTI Data.
September 9, 2015 7:57 AM EDTGuggenheim reiterated a Buy rating on Tetraphase Pharmaceuticals (NASDAQ: TTPH), and cut the price target to $20.00 (from $60.00), on disappointing cUTI data.
Analyst Louise Chen commented, "Despite disappointing cUTI data, we are maintaining our BUY rating for TTPH shares, but we are lowering our price target from $60 to $20. The decrease in our PT is driven by downwards earnings revisions and multiple contraction. In... More
